AbbVie, Leidos, KKR And More On CNBC's 'Final Trades'
Portfolio Pulse from Avi Kapoor
On CNBC's 'Halftime Report Final Trades,' analysts discussed AbbVie, Leidos, iShares U.S. Healthcare ETF, and KKR. AbbVie reported strong Q2 earnings, Leidos showed stable earnings with revenue growth, iShares U.S. Healthcare ETF was recommended, and KKR received a Buy rating with a raised price target.
August 06, 2024 | 12:43 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
iShares U.S. Healthcare ETF was recommended by Stephanie Link of Hightower. The ETF fell 2.6% during Monday's session.
The recommendation may attract investor interest, but the recent price drop suggests caution. The ETF's performance will depend on the broader healthcare sector.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 80
POSITIVE IMPACT
AbbVie reported Q2 adjusted EPS of $2.65, beating the consensus of $2.57, with net revenues of $14.46 billion, up 4.3%. Despite strong earnings, shares fell 2.6%.
AbbVie beat both EPS and revenue estimates, indicating strong performance. However, the stock fell, possibly due to broader market conditions or profit-taking. The strong earnings should support a positive outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
KKR posted Q2 earnings of 72 cents per share on sales of $4.17 billion. Citigroup maintained a Buy rating and raised the price target from $130 to $150.
KKR's strong earnings and the raised price target from Citigroup indicate positive sentiment and potential for stock price appreciation.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100
POSITIVE IMPACT
Leidos reported better-than-expected Q2 fiscal 2024 earnings with 8% revenue growth to $4.13 billion, driven by demand across all customer segments.
Leidos' strong earnings and revenue growth indicate robust business performance, likely to positively impact the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 100